Moon Eun-Sang – CEO, SillaJen – South Korea
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
GL PharmTech (GLPT) has focused on developing improved versions of the currently marketed pharmaceutical products with reduced side effects, greater therapeutic efficacy and better patient compliance using our proprietary drug formulation and delivery technologies since 2002.
We have provided more than 50 pharmaceutical companies in Korea with value-added drug formulations and delivery technologies for generic and improved version of marketed drug.
We are now transitioning from a being a technology transfer-based operation to being a specialty pharmaceutical company capable of developing and delivering new product lines by ourselves from 2010. We are doing this based on intensive investment in various clinical studies of products currently in our pipelines and using our already-established drug delivery platform technologies.
Contact details:
#714 Jungang Induspia V, 137, Sagimakgol-ro,
Jungwon-gu, Seongnam, Gyeonggi-do, Korea
Tel: +82-31-739-5220(ext. 102)
Website: www.glpt.co.kr
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation…
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance…
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s…
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative…
Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the…
After a lengthy career at Novartis, Angie Kim recently started working at BMS Korea to develop the affiliate. She discusses diversifying the company’s portfolio and their footprint in Korea as…
Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers?…
See our Cookie Privacy Policy Here